Simsen Diagnostics AB Announces Collaboration with Sahlgrenska University Hospital for Pancreatic Cancer Study
Simsen Diagnostics AB, a leader in cancer monitoring, is pleased to announce a collaboration with Professor Peter Naredi and his research group at Sahlgrenska University Hospital. This partnership focuses on enhancing the detection and monitoring of pancreatic cancer, using Simsen Diagnostics’ technology, Simsen Personal.
Pancreatic cancer is one of the most deadly cancers, often diagnosed at an advanced stage. Early detection is challenging due to the limited sensitivity of current diagnostic tools. To overcome these obstacles, Naredi and his research group aim to investigate Simsen Diagnostics’ solution, Simsen Personal—a highly sensitive method for detecting and monitoring cancer DNA from blood samples. The collaboration seeks to utilize Simsen Personal aiming to identify the disease in its early stages.
Professor Peter Naredi, leading the research group at the Department of Surgery, Sahlgrenska University Hospital, stresses the importance of early detection. “The only chance for a cure is to detect tumors in the early stages so that they can be surgically removed. Our collaboration with Simsen Diagnostics offers a novel approach to achieving this goal.” said Naredi. Simsen Personal is designed to monitor patient-specific mutations, improving the sensitivity of cancer detection.
Naredi further explains: “We are utilizing Simsen Diagnostics’ ultrasensitive technology to identify specific traces of cancer in the blood of each individual patient. If we can identify such biomarkers in the blood, it may provide a way to detect cancer or precancerous stages early in at-risk patients.”
About Simsen Diagnostics
Simsen Diagnostics is a biotech startup focusing on transforming cancer monitoring. Specializing in designing patient-specific tests, Simsen Personal, the flagship solution, is based on ultrasensitive technology capable of detecting cancer years before standard-of-care tools. Founded in 2020 as a research spin-out from Sahlgrenska Academy, Simsen Diagnostics has experienced steady growth, gaining recognition from the pharmaceutical industry. Situated in BioventureHub at AstraZeneca Gothenburg, the company is at the forefront of providing innovative solutions in cancer monitoring.